Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Arrowhead Pharmaceuticals (ARWR) over the last 9 years, with Sep 2025 value amounting to $133.8 million.

  • Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) rose 11.67% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.8 million, marking a year-over-year increase of 11.67%. This contributed to the annual value of $133.8 million for FY2025, which is 11.67% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $133.8 million, which was down 3.80% from $139.0 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $139.0 million in Q2 2025 and a low of $103.7 million during Q3 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $123.3 million (2024), whereas its average is $120.8 million.
  • Data for Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 16.23% (in 2024) over the last 5 years.
  • Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $104.5 million in 2021, then climbed by 1.44% to $106.0 million in 2022, then climbed by 1.30% to $107.4 million in 2023, then grew by 16.23% to $124.8 million in 2024, then grew by 11.67% to $133.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $133.8 million for Q3 2025, versus $139.0 million for Q2 2025 and $134.5 million for Q1 2025.